Publications by authors named "M Miyata"
UBA1 is an E1 ubiquitin-activating enzyme that initiates the ubiquitylation of target proteins and is thus a key component of the ubiquitin signaling pathway. Three disorders are associated with pathogenic variants of the UBA1 gene: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome, lung cancer in never smokers (LCINS), and X-linked spinal muscular atrophy (XL-SMA, SMAX2). We here report a case of infantile respiratory distress syndrome followed by continuing neuromuscular symptoms.
View Article and Find Full Text PDFIntroduction: We aimed to determine the impact of prior antimicrobial treatment on recurrent Clostridioides difficile infection (CDI) based on days of antibiotic spectrum coverage (DASC) and predict the risk of recurrence to guide the selection of appropriate initial therapeutic agents.
Methods: We assessed the antimicrobial treatment administered to 195 patients with a history of CDI for 28 days before testing positive for C. difficile using DASC and illness severity using ATLAS scores.
Article Synopsis
- The study aimed to simulate and evaluate how disease stage, VF test frequency, clustering, and eye inclusion impact sample size calculations in retinitis pigmentosa clinical trials.
- VF tests were conducted across different disease stages, measuring the probability of detecting significant treatment effects at various levels, with data collected over approximately two years.
- Results indicated that using only one eye could significantly reduce the required sample size for detecting treatment differences, especially in moderate disease stages, while early disease stages and including both eyes also influenced this requirement.
Article Synopsis
- * A study of 38 HD patients who underwent surgery found that a majority (78.9%) had poor outcomes at discharge, and significant differences were noted in Glasgow Coma Scale (GCS) scores and hematoma volumes between patients with better and very poor outcomes.
- * Despite the overall poor surgical outcomes, 21.1% of patients achieved a favorable modified Rankin Scale (mRS) score of 4 or less; patients with a GCS > 9 or hemat